

ASYMMETRIC SYNTHESIS OF RHOPALOIC ACID A ANALOGUES AND THEIR BIOLOGICAL PROPERTIES


Hiroko Nishitani, Asami Sasaoka, Munetaka Tokumasu, and Katsuo Ohkata*

Department of Chemistry, Faculty of Science, Hiroshima University,
1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan

Abstract - Some of rhopaloic acid A analogues were synthesized and their bioactivity was investigated on the basis of the inhibition of gastrulation of sea urchin embryos.

The interesting biological activity of rhopaloic acid A [(+)-**1**], a potent cytotoxic agent, which was isolated from a marine sponge, *Rhopalooides* sp.,¹ may be attributed to the structurally unique feature of having a hydrophilic tetrahydropyranylacrylic acid moiety connected to a hydrophobic isoprenoid part.² In order to investigate the structure-activity relationships of this compound, 5-geranyl and 5-tetradecyl derivatives (**2**) and (**3**) were prepared by the method as described previously (Scheme 2).³ We were also interested in whether the absolute configuration of the pyran ring affects to the activity. Therefore, we stereoselectively synthesized a pair of enantiomers (*2R,5R*)-**2** and (*2S,5S*)-**2** and a racemic *trans*-**3**.


Scheme 1



Carboxylic acid (**5**) was prepared by way of the malonic ester synthesis starting from geraniol (**4**). The Evans' asymmetric alkylation of *N*-acyl-oxazolidinone (**6**) was utilized for asymmetric construction of the stereogenic center in (*2R,5R*)-**2** (Scheme 2). The lithium enolate of (*R*)-**6** was treated with allyl bromide at -78 to 25 °C to give (*2R,4'R*)-**7**; $[\alpha]_{\text{D}}^{25} -47.0^\circ$; as a pure diastereomer (51% yield, 98% de).⁴ Reduction of (*2R,4'R*)-**7** with LiBH_4 gave (*R*)-**8**; $[\alpha]_{\text{D}}^{25} +1.4^\circ$, quantitatively. The optical purity of the

allylation product [(*R*)-**8**] was established by conversion of the alcohol into its benzoate. The benzoate was analyzed on a DAICEL-OJ CHIRAL column (hexane). According to the chelation model of the enolate intermediate, the absolute configuration of (*2R,4'R*)-**7** was predicted to be *2R*.⁵ Following the protection of the alcohol [(*R*)-**8**] with a *tert*-butyldimethylsilyl group, the silyl ether [(*R*)-**9**] was subjected to regioselective hydroboration with 9-BBN reagent followed by oxidation with H₂O₂ to give (*R*)-**10** (84%). Swern oxidation of (*R*)-**10** was converted to (*R*)-**11** in 60% yield.

Scheme 2



Reagents and conditions: a. PPh₃ (1.2 eq), CBr₄ (1.2 eq), CH₂Cl₂, 0 °C, 30 min; b. 1) NaH (1.0 eq), CH₂(CO₂Me)₂ (4.0 eq), THF, 0 to 25 °C, 13 h, 80% (2 steps); 2) NaCl (1.0 eq), H₂O (2 eq), DMF, reflux, 20 h, 85%; 3) aq. 3 M KOH (excess), THF, reflux, 20 h, 91%; c. Et₃N (1.2 eq), PivCl (1.2 eq), CH₂Cl₂, then *N*-lithio-oxazolidin-2-one, THF, -78 to 25 °C, 10 h, 86%; d. LDA (1.1 eq), THF, -78 °C, 30 min, then allyl bromide (4 eq), -78 to 25 °C, 18 h, 51%; e. LiBH₄ (4 eq), THF, 0 °C, 3 h, 76%; f. TBSCl (1.2 eq), imidazole (2 eq), DMF, 3 h, 85%; g. 9-BBN (1.1 eq), THF, 0 to 25 °C, overnight, then aq. 7 M NaOH (4 eq), aq. 30% H₂O₂ (4 eq), 0 to 25 °C, overnight, 84%; h. DMSO (2 eq), (COCl)₂ (1.2 eq), Et₃N (5 eq), CH₂Cl₂, -60 °C, 12 h, 60%; i. NaH (1.1 eq), Me₂CHSH (1.1 eq), (EtO)₂P(O)C(=CH₂)CO₂Me (1.2 eq), THF, 0 °C, 10 min, then (*R*)-**11**, 0 °C, 13 h, 59% (*E/Z* = 6/94); j. MeI (excess), AgBF₄ (3 eq), CH₂Cl₂, 25 °C, 1 h, then TBAF (3 eq), THF, 25 °C, 30 min, 28%; k. aq. 1 M LiOH (excess), THF, reflux, 18 h, 53%.


The modified Wittig-Horner-Emmons reaction of (*R*)-**11** with (EtO)₂P(O)C(=CH₂)CO₂Me in the presence of NaSCHMe₂ at 0 °C furnished α,β-unsaturated ester [(*R*)-**12**], the *E/Z* ratio being 6/94. The geometry of the product was determined based on relative chemical shifts of the ¹H NMR signals and with DIF-NOE. When 3-*H* of the *E*-isomer was irradiated, the intensity of 2-CH₂-S signal was enhanced with 8.2%. Reaction of *Z*-(*R*)-**12** with MeI/AgBF₄ followed by desilylation with TBAF afforded a mixture of *cis*- and

trans-tetrahydropyranylacrylate derivatives [(2*R*,5*R*)-**13**] in 28% yield (*cis/trans* = 1/9) in one pot reaction. The assignment of relative stereochemistry of *trans*-(2*R*,5*R*)-**13** was done by the ¹H NMR considerations: $J_{5,6-ax} = 11.2$ Hz, $J_{5,6-eq} = 3.9$ Hz. When 6-*ax*-H at δ 3.17 was irradiated, the intensity enhancement of 2-*H* at δ 4.02 by 8.2% was observed. The stereochemistry in the formation of pyranyl acrylate was rationalized by invoking a model of a chair-like transition state in which the long-chain alkyl group is located at the equatorial position. Hydrolysis of (2*R*,5*R*)-**13** in aqueous 1 M LiOH gave (2*R*,5*R*)-**2** in 53% yield.

The synthesis of the enantiomer [(2*S*,5*S*)-**2**] was accomplished by the same route as preparation of (2*R*,5*R*)-**2**. Allylation of (*S*)-**6** attached (*S*)-4-benzyloxazolidin-2-one as the chiral auxiliary by the same synthetic route to give (2*S*,4'*S*)-**7** (64%) in which the configuration at C-2 position was expected to be *S*. Successive conversion of (2*S*,4'*S*)-**7** afforded (2*S*,5*S*)-**2**; $[\alpha]_D^{25} -39.3^\circ$.

On the other hand, 5-tetradecyltetrahydropyranyl derivative (*trans*-**3**) was synthesized from methyl palmitate (**14**) by way of the analogous methodology as shown in Scheme 3. The geometry of *trans*-**3** was also determined on the basis of the NOE in ¹H NMR.

Scheme 3



Reagents and conditions: a. LDA (1.1 eq), THF, -78°C , 30 min, then allyl bromide (4 eq), -78 to 25°C , 18 h, 93%; b. LiAlH₄ (1.5 eq), THF, 0°C , 3 h; c. TBSCl (1.2 eq), imidazole (2 eq), DMF, 3 h, 92% (2 step); d. 9-BBN (1.1 eq), THF, 0 to 25°C , overnight, then aq. 12 M NaOH (4 eq), aq. 30% H₂O₂ (4 eq), 0 to 25°C , overnight, 88%; e. DMSO (2 eq), (COCl)₂ (1.1 eq), Et₃N (5 eq), CH₂Cl₂, -60°C , 12 h, 80%; f. NaH (1.4 eq), Me₂CHSH (1.3 eq), (EtO)₂P(O)C(=CH₂)CO₂Me (1.2 eq), THF, 0°C , 10 min, then **19**, 0°C , 13 h, 61% (*E/Z* = 1/9); g. MeI (4 eq), AgBF₄ (2 eq), CH₂Cl₂, 25°C , 5 h then TBAF (4 eq), THF, 25°C , 14 h, 25%; h. aq. 1 M LiOH (excess), THF, reflux, 19 h, 73%.

The structure-activity relationships of rhopalolic acid A [(+)-**1**] as an inhibitor of gastrulation of sea urchin embryos were examined using the synthetic rhopalolic acid A, (2*R*,5*S*)-5-geranyl derivative (2*R*,5*R*)- and (2*S*,5*S*)-**2**, and 5-tetradecyl derivative (*trans*-**3**).⁶ Natural type rhopalolic acid A (**1**), which was prepared by asymmetric synthesis,³ inhibited the activity with the gastrulation of sea urchin embryos 50%-inhibition (IC₅₀) of about 0.52 μM , confirming it as the same degree of a potent inhibitor as the isolated sample (IC₅₀

0.5 μM) from a marine sponge, *Rhopaloeides* sp.¹ The related analogues (2*R*,5*R*)-**2** and (2*S*,5*S*)-**2** bearing a geranyl group more weakened the observed inhibition (IC_{50} 20 μM and 40 μM), respectively. The bioassay studies in racemic *trans*-**3** bearing a tetradecyl group showed drastically reduced activity (IC_{50} 320 μM).

ACKNOWLEDGMENTS

The measurements of NMR and HRMS were made using JEOL JNM-GSX270, JNM-LA500, and JMS-SX102A, respectively, at the Instrument Center for Chemical Analysis, Hiroshima University.

REFERENCES AND NOTES

- (a) S. Ohta, M. Uno, M. Yoshimura, Y. Hiraga, and S. Ikegami, *Tetrahedron Lett.*, 1996, **37**, 2265. (b) Related natural product, hippospongiic acid A, was isolated from the other marine sponge: S. Ohta, M. Uno, M. Tokumasu, Y. Hiraga, and S. Ikegami, *Tetrahedron Lett.*, 1996, **37**, 7765.
- (a) E. D. de Silva and P. J. Scheuer, *Tetrahedron Lett.*, 1980, **21**, 1611; S. Katsumura, Q. Han, S. Fujiwara, S. Isoe, H. Nishimura, S. Inoue, and K. Ikeda, *Bioorg. Med. Chem. Lett.*, 1992, **2**, 1267; M. Tsuda, H. Shigemori, M. Ishibashi, T. Sasaki, and J. Kobayashi, *J. Org. Chem.*, 1992, **57**, 3503. (b) W. H. Gerwick, P. J. Proteau, D. G. Nagle, E. Hamel, A. Blokhin, and D. L. Slate, *J. Org. Chem.*, 1994, **59**, 1243; A. V. Blokhin, H.-D. Yoo, R. S. Geraldts, D. G. Nagle, W. H. Gerwick, and E. Hamel, *Mol. Pharmacol.*, 1995, **48**, 523.
- R. Takagi, A. Sasaoka, S. Kojima, and K. Ohkata, *Chem. Commun.*, 1997, 1887; R. Takagi, A. Sasaoka, H. Nishitani, S. Kojima, Y. Hiraga, and K. Ohkata, *J. Chem. Soc., Perkin Trans. 1*, 1998, 925; R. Takagi, A. Sasaoka, S. Kojima, and K. Ohkata, *Heterocycles*, 1997, **45**, 2313; R. Takagi, *Thesis*, 1998, Hiroshima University.
- All new compounds have been fully characterized by NMR and gave satisfactory exact MS. Spectral data for **2** and **3**: for **2**: ^1H NMR (270 MHz, CDCl_3) δ 1.16-1.46 (m, 2H), 1.48-1.74 (m, 1H), 1.58 (s, 3H), 1.60 (s, 3H), 1.68 (s, 3H), 1.83-2.08 (m, 8H), 3.19 (t, $J = 11.2$ Hz, 1H), 4.06 (ddd, $J = 11.2, 4.4, 2.0$ Hz, 1H), 4.13 (d, $J = 10.7$ Hz, 1H), 5.05-5.14 (m, 2H), 5.93 (s, 1H), 6.38 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 16.1, 17.7, 25.7, 26.6, 29.7, 29.9, 31.7, 36.4, 39.8, 73.8($\times 2$), 121.4, 124.2, 127.4, 137.2($\times 2$), 143.4, 167.2; HRMS m/z : found 292.2027 [M^+] (Calcd for $\text{C}_{18}\text{H}_{28}\text{O}_3$ 292.2038); for **3**: ^1H NMR (500 MHz, CDCl_3) δ 0.88 (t, $J = 6.9$ Hz, 3H), 1.04-1.44 (m, 28H), 1.50-1.67 (m, 1H), 1.94 (d, $J = 11.0$ Hz, 2H), 3.16 (t, $J = 11.3$ Hz, 1H), 4.05 (ddd, $J = 11.3, 4.0, 1.2$ Hz, 1H), 4.13 (d, $J = 11.3$ Hz, 1H), 5.92 (s, 1H), 6.37 (s, 1H); ^{13}C NMR (125 MHz, CDCl_3) δ 14.1, 22.1, 26.6, 29.4, 29.5, 29.6($\times 4$), 29.7($\times 3$), 29.8, 30.3, 31.9, 32.3, 35.5, 74.1, 76.2, 126.8, 140.8, 169.3; HRMS m/z : found 352.3019 [M^+] (Calcd for $\text{C}_{22}\text{H}_{40}\text{O}_3$ 352.2977).
- D. A. Evans, M. D. Ennis, and D. J. Mathre, *J. Am. Chem. Soc.*, 1982, **104**, 1737; D. A. Evans, T. C. Britton, J. A. Ellman, and R. L. Dorow, *J. Am. Chem. Soc.*, 1990, **112**, 4011; P. P. Waid, G. A. Flynn, E. W. Huber, and J. S. Sabol, *Tetrahedron Lett.*, 1996, **37**, 4091; W. He, E. Pinard, and L. A. Paquette, *Helv. Chim. Acta*, 1995, **78**, 391.
- S. Ikegami, K. Kawada, Y. Kimura, and A. Suzuki, *Agric. Biol. Chem.*, 1979, **43**, 161.